Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9929487 | The American Journal of Medicine | 2005 | 6 Pages |
Abstract
Infliximab was found to be an alternative treatment with a relatively acceptable toxicity profile, despite the fact that two patients developed pulmonary tuberculosis. After the third year of therapy, 59% of patients continued to be treated with infliximab. The concomitant use of methotrexate was associated with the continuation of infliximab therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Paraskevi V. MD, Yannis MD, Spyros N. MD, Dimitrios V. MD, Themistoklis I. MD, Alexandros A. MD,